Fight or flight? - Diversification vs. Rx-focus in big pharma's quest for sustained growth
This study is based on a global quantitative survey supported by in-depth desk research. The survey results were validated in over 50 CEO and board level face-to-face interviews with top decision makers of leading pharmaceutical groups.
According to 65% of pharma executives, the pharmaceutical industry is currently experiencing a strategic crisis. Changing healthcare environments, budget pressures, challenging market access as well as massive patent expiries ask for a review of the traditional business model focusing exclusively on high margin, patent-protected innovative medicine.
The majority of pharma executives think of diversification as a potential way out of the strategic crisis.